



Anxiety sensitivity as a transdiagnostic risk factor for trajectories of adverse posttraumatic neuropsychiatric sequelae in the AURORA study

Nicole A. Short^{a,b,*}, Sanne J.H. van Rooij^c, Vishnu P. Murty^d, Jennifer S. Stevens^c, Xinming An^a, Yinyao Ji^e, Samuel A. McLean^{e,f}, Stacey L. House^g, Francesca L. Beaudoin^h, Donglin Zengⁱ, Thomas C. Neylan^j, Gari D. Clifford^{k,l}, Sarah D. Linnstaedt^a, Laura T. Germiné^{m,n,o}, Kenneth A. Bollen^p, Scott L. Rauch^{m,o,q}, John P. Haran^r, Christopher Lewandowski^s, Paul I. Musey Jr.^t, Phyllis L. Hendry^u, Sophia Sheikh^u, Christopher W. Jones^v, Brittany E. Punches^{w,x}, Robert A. Swor^y, Meghan E. McGrath^z, Lauren A. Hudak^{aa}, Jose L. Pascual^{ab,ac}, Mark J. Seamon^{ac,ad}, Elizabeth M. Datner^{ae,af}, Claire Pearson^{ag}, David A. Peak^{ah}, Roland C. Merchant^{ai}, Robert M. Domeier^{aj}, Niels K. Rathlev^{ak}, Brian J. O'Neil^{al}, Paulina Sergot^{am}, Leon D. Sanchez^{ai,an}, Steven E. Bruce^{ao}, Robert H. Pietrzak^{ap,aq}, Jutta Joormann^{ar}, Deanna M. Barch^{as}, Diego A. Pizzagalli^{at}, John F. Sheridan^{au,av}, Jordan W. Smoller^{aw,ax}, Steven E. Harte^{ay,az}, James M. Elliott^{ba,bb,bc}, Ronald C. Kessler^{bd}, Karestan C. Koenen^{be}, Tanja Jovanovic^{bf}

^a Institute for Trauma Recovery, Department of Anesthesiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27559, USA

^b Department of Psychology, University of Nevada, Las Vegas, NV, 89154, USA

^c Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, 30329, USA

^d Department of Psychology, Temple University, Philadelphia, PA, 19121, USA

^e Institute for Trauma Recovery, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27559, USA

^f Department of Emergency Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27559, USA

^g Department of Emergency Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA

^h Department of Epidemiology, The Brown University School of Public Health, Providence, RI, 02930, USA

ⁱ Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, 27559, USA

^j Departments of Psychiatry and Neurology, University of California San Francisco, San Francisco, CA, 94143, USA

^k Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, 30332, USA

^l Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA

^m Institute for Technology in Psychiatry, McLean Hospital, Belmont, MA, 02478, USA

ⁿ The Many Brains Project, Belmont, MA, 02478, USA

^o Department of Psychiatry, Harvard Medical School, Boston, MA, 02115, USA

^p Department of Psychology and Neuroscience & Department of Sociology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27559, USA

^q Department of Psychiatry, McLean Hospital, Belmont, MA, 02478, USA

^r Department of Emergency Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01655, USA

^s Department of Emergency Medicine, Henry Ford Health System, Detroit, MI, 48202, USA

^t Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA

^u Department of Emergency Medicine, University of Florida College of Medicine - Jacksonville, Jacksonville, FL, 32209, USA

^v Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ, 08103, USA

^w Department of Emergency Medicine, Ohio State University College of Medicine, Columbus, OH, 43210, USA

^x Ohio State University College of Nursing, Columbus, OH, 43210, USA

^y Department of Emergency Medicine, Oakland University William Beaumont School of Medicine, Rochester, MI, 48309, USA

^z Department of Emergency Medicine, Boston Medical Center, Boston, MA, 02118, USA

^{aa} Department of Emergency Medicine, Emory University School of Medicine, Atlanta, GA, 30329, USA

^{ab} Department of Surgery, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, 19104, USA

^{ac} Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

^{ad} Department of Surgery, Division of Traumatology, Surgical Critical Care and Emergency Surgery, University of Pennsylvania, Philadelphia, PA, 19104, USA

^{ae} Department of Emergency Medicine, Einstein Healthcare Network, Philadelphia, PA, 19141, USA

^{af} Department of Emergency Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA

* Corresponding author. University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.

E-mail address: nicole.short@unlv.edu (N.A. Short).

<https://doi.org/10.1016/j.jpsychires.2022.09.027>

Received 6 May 2022; Received in revised form 16 August 2022; Accepted 16 September 2022

Available online 27 September 2022

0022-3956/© 2022 Elsevier Ltd. All rights reserved.

- ^{a8} Department of Emergency Medicine, Wayne State University, Ascension St. John Hospital, Detroit, MI, 48202, USA
- ^{a9} Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA
- ^{a1} Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
- ^{a1} Department of Emergency Medicine, Saint Joseph Mercy Hospital, Ypsilanti, MI, 48197, USA
- ^{ak} Department of Emergency Medicine, University of Massachusetts Medical School-Baystate, Springfield, MA, 01107, USA
- ^{a1} Department of Emergency Medicine, Wayne State University, Detroit Receiving Hospital, Detroit, MI, 48202, USA
- ^{am} Department of Emergency Medicine, McGovern Medical School at UTHealth, Houston, TX, 77030, USA
- ^{an} Department of Emergency Medicine, Harvard Medical School, Boston, MA, 02115, USA
- ^{a0} Department of Psychological Sciences, University of Missouri - St. Louis, St. Louis, MO, 63121, USA
- ^{ap} National Center for PTSD, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven, CT, 06516, USA
- ^{a9} Department of Psychiatry, Yale School of Medicine, New Haven, CT, 06510, USA
- ^{ar} Department of Psychology, Yale University, New Haven, CT, 06510, USA
- ^{a5} Department of Psychological & Brain Sciences, Washington University in St. Louis, St. Louis, MO, 63130, USA
- ^{a1} Division of Depression and Anxiety, McLean Hospital, Belmont, MA, 02478, USA
- ^{au} Division of Biosciences, Ohio State University College of Dentistry, Columbus, OH, 43210, USA
- ^{av} Institute for Behavioral Medicine Research, OSU Wexner Medical Center, Columbus, OH, 43211, USA
- ^{aw} Department of Psychiatry, Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, 02114, USA
- ^{ax} Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, 02142, USA
- ^{ay} Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
- ^{a2} Department of Internal Medicine-Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
- ^{ba} Kolling Institute, University of Sydney, St Leonards, New South Wales, 2065, Australia
- ^{bb} Faculty of Medicine and Health, University of Sydney, Northern Sydney Local Health District, New South Wales, 2006, Australia
- ^{bc} Physical Therapy & Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60208, USA
- ^{bd} Department of Health Care Policy, Harvard Medical School, Boston, MA, 02115, USA
- ^{be} Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, 02115, USA
- ^{bf} Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, 48202, USA

ARTICLE INFO

Keywords:

Anxiety sensitivity
 Posttraumatic stress
 Depression
 Anxiety
 Pain
 Tztrauma

ABSTRACT

Anxiety sensitivity, or fear of anxious arousal, is cross-sectionally associated with a wide array of adverse posttraumatic neuropsychiatric sequelae, including symptoms of posttraumatic stress disorder, depression, anxiety, sleep disturbance, pain, and somatization. The current study utilizes a large-scale, multi-site, prospective study of trauma survivors presenting to emergency departments. Hypotheses tested whether elevated anxiety sensitivity in the immediate posttrauma period is associated with more severe and persistent trajectories of common adverse posttraumatic neuropsychiatric sequelae in the eight weeks posttrauma. Participants from the AURORA study ($n = 2,269$ recruited from 23 emergency departments) completed self-report assessments over eight weeks posttrauma. Associations between heightened anxiety sensitivity and more severe and/or persistent trajectories of trauma-related symptoms identified by growth mixture modeling were analyzed. Anxiety sensitivity assessed two weeks posttrauma was associated with severe and/or persistent posttraumatic stress, depression, anxiety, sleep disturbance, pain, and somatic symptoms in the eight weeks posttrauma. Effect sizes were in the small to medium range in multivariate models accounting for various demographic, trauma-related, pre-trauma mental health-related, and personality-related factors. Anxiety sensitivity may be a useful transdiagnostic risk factor in the immediate posttraumatic period identifying individuals at risk for the development of adverse posttraumatic neuropsychiatric sequelae. Further, considering anxiety sensitivity is malleable via brief intervention, it could be a useful secondary prevention target. Future research should continue to evaluate associations between anxiety sensitivity and trauma-related pathology.

Traumatic event exposure is common in the United States (US), with up to 90% of the population reporting lifetime exposure to a traumatic event (Kilpatrick et al., 2013). Of these, approximately 40 million present annually to emergency departments (EDs) for care following traumatic event exposure such as motor vehicle collision (MVC; Roberts et al., 2011). Unfortunately, adverse posttraumatic neuropsychiatric sequelae (APNS) are common and incur substantial burden on the health of an individual following trauma exposure. Specifically, posttraumatic stress disorder (PTSD) is the mental health condition most closely linked to trauma exposure, symptoms of which include re-experiencing the event, avoidance of reminders of the event, negative alterations in cognition and mood, as well as alterations in arousal and reactivity (American Psychiatric Association, 2013). Clinically significant PTSD symptoms occur in approximately 10% of trauma survivors, though this proportion varies depending on trauma type (Kilpatrick et al., 2013). Related symptoms are also common: many trauma survivors report clinically significant anxiety and/or depression (Kenardy et al., 2018), insomnia (Milanek et al., 2019), as well as pain and somatic symptoms, including headaches, dizziness, and nausea (Ulirsch et al., 2014), following trauma exposure. Although these symptoms are discrete and diverse, they are often comorbid, rather than presenting separately. For example, PTSD symptoms often co-occur with sleep disturbance (Short

et al., 2018), pain (Asmundson et al., 2002), and depression (Momartin et al., 2004). These posttrauma symptoms can become chronic and pose a significant burden to society as well as the individual (Kessler, 2000). Although trauma survivors receive care for physical injuries during their ED visits (Grega et al., 2017), there are no widely available interventions to prevent or reduce the burden of APNS. This raises the need to identify and evaluate potential malleable risk factors for these symptoms.

Anxiety sensitivity (AS) is defined as fear of anxious arousal (e.g., fears a racing heart indicates a heart attack; Reiss et al., 1986). AS is a transdiagnostic risk factor for the development of APNS that is considered to be trait-like but malleable via brief, cognitive behavioral interventions (Schmidt et al., 2014). Although initially linked with panic disorder (McNally, 2002), AS is now widely considered to be a transdiagnostic risk factor across anxiety-related and other mental health conditions (Smits et al., 2019). Specifically, cross-sectional research in various samples links AS with PTSD (Lang et al., 2002; Taylor, 2003), depression and anxiety (Allan et al., 2016; Paulus et al., 2018), insomnia and nightmares (Levin et al., 2009; Rogers et al., 2016; Short et al., 2015), pain (Ocañez et al., 2010; Zvolensky et al., 2020), and somatic symptoms (Hensley and Varela, 2008). Meta-analytic studies indicate that although AS is elevated across various conditions, it may be most

closely linked with fear and arousal-based disorders, including PTSD (Naragon-Gainey, 2010).

Relatively few prospective studies have examined whether AS predicts the development of APNS after trauma. The few studies available suggest AS may prospectively predict PTSD, depression, and anxiety symptoms after sexual assault (Short et al., *in press*), and PTSD symptoms in response to a campus shooting (Boffa et al., 2016) and other stressful life events that may not qualify as a Criterion A trauma such as childbirth (American Psychiatric Association, 2013; Keogh et al., 2002). AS may heighten risk for APNS by exacerbating normative post-traumatic stress, which is interpreted as threatening by those with high AS. For example, an individual with high AS may interpret intrusive memories as signs one is “going crazy,” or that increased heart rate in response to trauma reminders is indicative of impending cardiac arrest (Taylor, 2003). As such, those with high AS may experience increased physiological reactivity and distress in response to trauma reminders (McHugh et al., 2017), motivating avoidance, and maintaining PTSD and related symptoms. Despite this theoretical rationale and early promising empirical research, no studies to our knowledge have examined whether AS predicts symptom trajectories of a diverse set of trauma symptoms (i.e., pain, somatic, and insomnia symptoms) in a large sample of mixed trauma survivors recruited immediately posttrauma.

The current study is the first large-scale, multi-site, prospective study of trauma survivors presenting to EDs to assess whether elevated AS in the immediate posttrauma period is associated with more severe and persistent trajectories of common APNS (PTSD, depression, anxiety, pain, insomnia, and somatic symptoms) in the eight weeks posttrauma. Profiles of APNS based on growth mixture modeling were used as outcomes because of the complex temporal nature of APNS following trauma. Specifically, the vast majority of trauma survivors will experience heightened APNS, particularly PTSD symptoms, in the aftermath of trauma. This is an expected and normal part of the trauma recovery process, and not pathological. However, the majority of survivors' symptoms will recover naturally over time, while a small but significant minority of individuals' symptoms will remain heightened and clinically significant (Santiago et al., 2013). Therefore, utilizing trajectory profiles enables the identification of individuals whose symptoms do *not* resolve naturally over time, and thus are at risk of developing chronic APNS. Indeed, prior prospective research of a smaller sample ($n=330$) of physically injured trauma survivors found four latent classes of APNS (only examining PTSD and depressive symptoms): chronic distress, delayed distress, recovered, and resilience (deRoos-Cassini et al., 2010), indicating the importance of examining trajectories of symptoms over time. In regard to the trajectories of APNS following trauma exposure, we hypothesized that 1) elevated AS measured in the two weeks posttrauma will be associated with increased risk for belonging in classes with severe and persistent trajectories of transdiagnostic APNS (i.e., PTSD, depression, anxiety, sleep disturbance, pain, and somatic symptoms) in the eight weeks posttrauma; 2) the associations between AS and APNS will persist after accounting for a variety of important covariates, including sociodemographic, trauma-related, pre-trauma mental health-related, and personality-related factors (i.e., neuroticism); and 3) based on prior research (Naragon-Gainey, 2010), the strongest associations will be found between AS and anxiety and hypervigilance-related symptoms.

1. Methods

1.1. Participants and procedures

AURORA study recruitment occurred from September 2017 to December 2020. The current sample is drawn from the third data release. Patients presenting for emergency care within 72h of trauma exposure at 23 participating study sites were screened for eligibility. Inclusion criteria included: age of 18–75 years, fluent in spoken and written English, alert and oriented at the time of ED presentation, ability

to follow enrollment protocol and use a smart phone, possessed a smartphone for >1 year. Qualifying traumatic events included motor vehicle collision, physical assault, sexual assault, fall >10 feet, or mass casualty incidents. Exclusion criteria included: solid organ injury, significant hemorrhage, need for a chest tube, or likely to be admitted for >72h. A total of 2,654 individuals were included in the entire sample, with 2,305 completing an AS assessment, 2,269 of whom had trajectory data for at least one class of symptoms and were thus included in the final sample for the current study.¹

Potentially eligible participants were approached by site research assistants who screened participants, obtained written, informed consent, and administered a brief ED assessment. After enrollment, participants received a two-week self-report assessment which was completed online. They also received surveys on their smart phones in the eight weeks after trauma, which included a rotating set of self-report questions on a variety of APNS (detailed below). Participants were compensated for their participation in all assessments. AURORA study protocol is described in greater detail elsewhere (McLean et al., 2019). Prior studies have discussed clinical outcomes for AURORA participants (Kessler et al., 2020), a clinical risk tool for PTSD which includes AS items (Ziobrowski et al., 2021), and the analysis of classes of symptom trajectories (without considering AS as a risk factor of these outcomes; Beaudoin et al., *under review*). However, the current results have not been published previously. All procedures were approved by a central Institutional Review Board (IRB) and local IRBs as relevant.

1.2. Measures

Anxiety Sensitivity (AS). The Anxiety Sensitivity Index (ASI; Reiss et al., 1986) was adapted and used to measure AS two weeks after participants presented to emergency care. To maintain assessment brevity in this large study, only three of 16 items were used, with responses rated on a 5-point Likert scale ranging from 0 (*very little*) to 4 (*very much*). Items included were: Item 2, “When I cannot keep my mind on a task, I worry that I might be going crazy; Item 14, “Unusual body sensations scare me;” and Item 15, “When I am nervous, I worry that I might be mentally ill.” The possible score range for the brief ASI was 0–12, with higher scores indicating higher levels of AS. The ASI has strong psychometric properties (Reiss et al., 1986). This brief ASI was used in a prior study of recent trauma survivors and demonstrated good internal consistency ($\alpha = 0.89$; Short et al., *in press*).

APNS outcomes. Self-report surveys were administered via participants' smart phones using the Mindstrong Discovery™ application at six time points in the eight weeks after trauma (see [Supplementary Table 1](#) for numbers of and a list of items, and precise timing of when administered). Items assessing the a priori-identified constructs of pain, somatic symptoms, sleep, avoidance, re-experiencing, hyperarousal, anxiety, and depression in the past 24 h were administered on a rotating schedule to ensure even assessment of each construct ([Supplementary Table 1](#)). Items were drawn from validated measures including the PTSD Checklist, PROMIS scales, and Insomnia Severity Index (Cella et al., 2010; Morin et al., 2011; National Center for PTSD, 2019), and shortened/adapted as needed to assess state symptoms, as described elsewhere (Beaudoin et al., *under review*; McLean et al., 2019). [Supplementary Table 2](#) provides support for reliability of these measures.

Covariates. Demographics. Sociodemographic data were collected in the ED regarding gender, age, highest grade achieved, income, race/ethnicity, employment, and marital status. **Trauma-related variables.**

¹ Details regarding missing trajectory data were as follows. The class with the most missing data was sleep and nightmares ($n = 27$ of the final sample), followed by depression ($n = 25$), anxiety and arousal ($n = 25$), somatic symptoms and mental fatigue ($n = 19$), re-experiencing and avoidance ($n = 18$), and pain ($n = 10$).

Information regarding the trauma was collected in the ED. Whether or not participants sustained a traumatic brain injury as defined by a diagnosed concussion or if the participant reported their head was hit during the trauma, along with loss of consciousness, amnesia, or disorientation (McLean et al., 2009). Whether or not participants were admitted to the ED was recorded, along with the severity of injury as assessed by the Abbreviated Injury Scale (AIS; Loftis et al., 2018). Participants also self-reported on peritraumatic dissociation using the Michigan Critical Events Perception Scale (MCEPS; Michaels et al., 1999). *Personality.* The Ten Item Personality Index (TIPI; Gosling et al., 2003) was administered at two weeks posttrauma and was used in the current study to index neuroticism. *Pre-trauma mental health symptoms.* Pre-trauma mental health symptoms in the 30 days prior to the event were retroactively assessed at the initial ED visit by altering the instructions to specify this timeframe in each measure. Specific measures were as follows: the Patient Reported Outcome Information System (PROMIS; Cella et al., 2010) evaluated pre-trauma depression and anxiety, the Insomnia Severity Index (ISI; Morin et al., 2011) assessed pre-trauma insomnia symptoms, the PTSD Checklist-5 (PCL-5; Weathers et al., 2013) measured pre-trauma PTSD symptoms (for the PCL-5, individuals who denied disturbing memories; feeling upset when reminded of the trauma; avoiding reminders; feeling cutoff; feeling irritable; and difficulty concentrating were not given the full PCL-5 and their pre-trauma PTSD diagnoses were coded as no pre-trauma PTSD [0]), a pain Numeric Rating Scale (NRS) assessed pre-trauma pain (Farrar et al., 2001), and pre-trauma somatic symptoms were assessed by a 20-item measure adapted from the Pennebaker Inventory of Limbic Languidness (Pennebaker and Watson, 1991) and the Rivermead Post-Concussion Symptoms Questionnaire (Potter et al., 2006) commonly used in studies of trauma survivors recruited from the ED (Ulirsch et al., 2014).

1.3. Data analytic plan

Trajectories for each posttrauma symptom (i.e., re-experiencing, avoidance, hyperarousal, pain, depression, insomnia, nightmares, anxiety, somatic symptoms, mental fatigue) were identified using self-reported state symptoms from the mobile phone-based surveys. Detailed methods and analytic techniques are described in Beaudoin et al. (under review; note the Beaudoin et al. results are related to a smaller initial dataset) and in the supplemental tables. In brief, R (R Core Team, 2022) was used to prepare data for analysis, and MPlus (Muthén and Muthén, 1998–2017) was used for model building. Joint measurement models were developed for each of the ten latent APNS constructs including all six timepoints (see Supplementary Table 2). Latent growth curve models were identified to establish trajectories for each construct, and growth mixture modeling was used to estimate latent trajectory classes. The number of latent classes for each construct was determined by analysis of model fit, BIC, percentage of participants in each latent class, and theoretical expectations/clinical utility. Models with convergence issues or including latent classes with less than 5% participants were excluded first. Afterwards, BIC was used to select the best model. For models with similar BICs, theoretical expectations and clinical utility were used to guide final model selection. Qualitative descriptors of these empirically derived classes were developed by visually inspecting the data. Each participant was assigned to a class based on these analyses, and these class variables were used as dependent variables in the current analyses. Data were treated as missing at random after confirmation that missingness was not associated with the constructs of interest (Beaudoin et al., under review).

Using these class trajectories, general linear models (GLMs) in SPSS Version 26.0 (IBM Corp, 2019) were used to determine whether self-reported AS assessed two weeks posttrauma predicted class membership in classes with more severe or persistent APNS over eight weeks posttrauma. First, a series of 10 univariate GLMs with AS as a predictor of each construct in separate models were conducted to assess whether

AS predicted these constructs and levels of AS in each class. Simple contrasts were used to evaluate whether AS differed across classes when the omnibus test was significant. Second, the same 10 analyses were estimated using multivariate GLMs with the following covariates: race and ethnicity, employment, and marital status as categorical variables, and gender, age, highest grade achieved, income, peritraumatic dissociation, injury severity, whether the participant was admitted to the ED, whether the participant had a likely concussion, pre-trauma anxiety symptoms, neuroticism, and pre-trauma symptoms for the dependent variable of interest (e.g., for re-experiencing symptoms, pre-trauma PTSD diagnostic status was a covariate; for pain, pre-trauma moderate or severe pain was a covariate) as continuous variables. Effect sizes were evaluated using eta-squared and partial eta-squared. Values of 0.01, 0.06, and 0.14 were considered small, medium, and large effect sizes, respectively (Cohen, 1988; Richardson, 2011). For the current analyses linking AS with APNS trajectories, individuals who were missing class data were dropped from analyses in which their data were missing.¹

2. Results

2.1. Descriptive statistics

Participants were majority women (63.5%), with an average age of about 36 years ($M = 35.82$, $SD = 13.07$). The largest proportion of participants was Black (49.8%), followed by white (34.7%), Hispanic (11.3%), and other (e.g., Asian, Native American; 3.7%). Education levels varied, with a slight majority attaining some college (53.5%). Most participants were employed (73.2%) and reported an income of \$35,000 or less (62.3%). Regarding trauma exposure, the majority experienced MVC (75.6%), were discharged home from the ED (93.9%), and had minimal physical injury (e.g., musculoskeletal strain; AIS $M = 1.19$, $SD = 0.42$). About one third had clinically significant PTSD symptoms prior to the current trauma exposure (31.8%). At eight weeks posttrauma (concurrent to when surveys assessing class trajectories ended), the majority of participants reported clinically significant new or worsening pain (77.1%), while large minorities reported clinically significant insomnia (40.1%), PTSD (38.0%), and depression (27.1%) (see Table 1).

2.2. Class trajectories

A brief summary of results is provided as trajectories are not the main focus of the current manuscript and detailed results are described in elsewhere (Beaudoin et al., under review). First, measurement models for each latent APNS construct demonstrated good fit (CFIs = 0.90–0.99, TLIs = 0.86–0.98, SRMRs = 0.01–0.06, RMSEAs = 0.04–0.11). Most did not have full measurement invariance over time (except Anxiety), likely due to the large sample size (differences over time were <5%). All APNS were best modeled using a piecewise linear trajectory except Anxiety (which was modeled as linear). For each APNS, 2 (sleep; CFI = 0.94, TLI = 0.93, SRMR = 0.04, RMSEA = 0.06), 3 (hyperarousal, depression, nightmares, anxiety, somatic symptoms; CFIs = 0.92–0.95, TLIs = 0.90–0.95, SRMRs = 0.03–0.05, RMSEAs = 0.06–0.09), or 4 (re-experiencing, avoidance, pain, mental fatigue; CFIs = 0.93–0.99, TLIs = 0.93–0.98, SRMRs = 0.03–0.05, RMSEAs = 0.04–0.07) classes of symptom trajectories were identified (see Table 2 for number and percentage of individuals in each class described qualitatively and Fig. 1 for a visual depiction of trajectories).

2.3. Univariate analyses of AS predicting class membership

AS was a significant predictor of trajectories of each trauma-related construct (all $ps < .001$), and AS significantly increased sequentially across each class based on the severity and persistence of symptoms, with the highest levels of AS found among those with the most severe and persistent symptoms (Table 2). AS was associated with higher levels

Table 1
Participant demographic and clinical characteristics (n = 2,269)

	n (%)
Age (M [SD])	35.82 (13.07)
Women	1440 (63.5)
Race/Ethnicity	
Hispanic	257 (11.3)
White	788 (34.7)
Black	1131 (49.8)
Other	85 (3.7)
Education	
Less than high school	166 (7.3)
High school or equivalent	84 (3.7)
Post-high school training not college/some college	1210 (53.5)
4-year degree	175 (7.7)
Graduate or professional degree	626 (27.7)
Annual Income	
≤\$19,000	721 (31.8)
\$19,001–35,000	692 (30.5)
\$35,001–50,000	325 (14.3)
\$50,001–75,000	198 (8.7)
\$75,001+	304 (13.4)
Work Status	
Employed	1660 (73.2)
Retired	54 (2.4)
Homemaker	52 (2.3)
Student	89 (3.9)
Unemployed/disabled/other	397 (17.5)
Trauma Type	
Motor vehicle collision	1715 (75.6)
Physical assault	207 (9.1)
Sexual assault	13 (0.6)
Fall <10'	33 (1.5)
Mass trauma event	10 (0.4)
Non-motorized collision	43 (1.9)
Fall >10' or unknown height	110 (4.8)
Poisoning	2 (0.1)
Animal-related	52 (2.3)
Burn	10 (0.4)
Other	74 (3.3)
PTSD prior to current trauma	722 (31.8)
Clinical outcomes at 8 weeks	
PTSD	863 (38.0)
Depression	616 (27.1)
Insomnia	807 (40.1)
Clinically significant new or worsening pain	1481 (77.1)
Anxiety (M [SD])	7.14 (4.57)

of PTSD symptoms, including re-experiencing, avoidance, and hyperarousal, with large effects. AS was associated with higher levels of pain, with a medium effect size. Those with higher levels of insomnia and nightmares also had higher levels of AS, with medium to large effects. AS was also associated with higher levels of depression and anxiety, with large effects. Finally, AS was associated with higher levels of somatic symptoms and mental fatigue, with medium to large effects.

2.4. Multivariate analyses of AS predicting class membership

In multivariate models including covariates, AS continued to be significantly associated with higher levels of symptoms in each construct (Table 3). Again, AS increased sequentially and significantly across classes, with the groups with the most severe/persistent APNS having the highest levels of AS. Elevated AS continued to be associated with higher PTSD symptoms, including re-experiencing, avoidance, and hyperarousal symptoms, with medium effects. Covariates significantly positively associated with worsened PTSD symptom trajectories (Supplementary Table 3) included identifying as a woman, older age, higher education, higher income level, peritraumatic dissociation, pre-trauma anxiety (for hyperarousal symptoms), neuroticism, and pre-trauma probable PTSD diagnosis (for arousal symptoms). AS was associated with worsened pain trajectories with a small to medium effect. Covariates positively associated with pain trajectories included identifying as

Table 2
Univariate general linear models of anxiety sensitivity levels by class trajectory membership.

	n (%)	M	SE	df	F	p	η ²
Re-experiencing				3, 2247	178.35	<.001	.19
Low	937 (41.6)	1.82	.09				
Moderate recovery	704 (31.3)	3.42	.11				
Moderate	468 (20.8)	4.63	.13				
High*	142 (6.3)	6.65	.24				
Avoidance				3, 2247	143.39	<.001	.16
Low	858 (38.1)	1.85	.10				
Moderate Recovery	453 (20.1)	2.90	.14				
Moderate	703 (31.2)	4.30	.11				
High*	237 (10.5)	5.52	.19				
Hyperarousal				2, 2241	301.30	<.001	.21
Low	980 (43.7)	1.76	.09				
Moderate	928 (41.4)	33.75	.09				
High*	336 (14.6)	5.98	.16				
Pain				3, 2255	66.43	<.001	.08
Low	288 (12.7)	1.99	.18				
Moderate Recovery	722 (32.0)	2.57	.11				
Moderate	810 (35.9)	3.35	.11				
High*	439 (19.4)	4.82	.15				
Depression				2, 2241	399.00	<.001	.26
Low	1072 (46.5)	1.65	.07				
Moderate	847 (37.7)	4.07	.11				
High*	325 (14.1)	6.17	.20				
Sleep				1, 2240	286.55	<.001	.11
Low	1159 (51.7)	2.18	.09				
High*	1083 (47.0)	4.34	.09				
Nightmares				2, 2239	314.91	<.001	.22
Low	1551 (69.2)	2.25	.07				
Moderate	542 (24.2)	5.06	.12				
High*	149 (6.6)	6.69	.23				
Anxiety				2, 2241	318.96	<.001	.22
Low	1178 (52.5)	1.89	.08				
Moderate	814 (36.3)	4.21	.10				
High*	252 (11.2)	6.21	.18				
Somatic Symptoms				2, 2247	219.94	<.001	.16
Low	1434 (63.7)	2.33	.08				

(continued on next page)

Table 2 (continued)

	<i>n</i> (%)	<i>M</i>	<i>SE</i>	<i>df</i>	<i>F</i>	<i>p</i>	<i>n</i> ²
Moderate	601 (26.7)	4.17	.12				
High*	215 (9.6)	6.35	.20				
Mental Fatigue				3, 2246	181.72	<.001	.20
Low	841 (37.4)	1.65	.10				
Moderate Recovery	155 (6.9)	3.25	.23				
Moderate	823 (36.6)	3.56	.10				
High*	431 (19.1)	5.56	.139				

Note: * = *p* < .001 in simple contrasts comparing the high/persistent class with each other class for each respective outcome.

Table 3

Estimates of anxiety sensitivity as a predictor of class membership in multivariate models after covarying for sociodemographic, trauma-related, pre-trauma mental health-related, and personality-related factors.

	<i>df</i>	<i>F</i>	<i>p</i>	<i>n</i> _p ²
Re-experiencing	1, 2004	167.95	<.001	.08
Avoidance	1, 2004	131.29	<.001	.06
Hyperarousal	1, 2004	182.87	<.001	.08
Pain	1, 2010	62.93	<.001	.03
Depression	1, 1963	213.95	<.001	.10
Sleep	1, 1980	74.25	<.001	.04
Nightmares	1, 1980	237.77	<.001	.11
Anxiety	1, 1998	208.91	<.001	.10
Somatic Symptoms	1, 1969	151.69	<.001	.07
Mental Fatigue	1, 1969	123.42	<.001	.06




Fig. 1. Visual depictions of latent class trajectories for each construct.

a woman, older age, higher education and income levels, peritraumatic dissociation, pre-trauma anxiety, neuroticism, and pre-trauma clinically significant pain.

Further, AS was associated with increased insomnia and nightmares, with small to medium and medium to large effects, respectively. Covariates associated with more severe sleep disturbance trajectories included older age (for insomnia), higher education and income (for nightmares), peritraumatic dissociation, neuroticism (for insomnia), pre-trauma anxiety (for nightmares), and pre-trauma insomnia symptoms. AS was associated with depression and anxiety with medium to large effects. Covariates predicting worsened depression and anxiety trajectories were: identifying as women (for anxiety), older age, higher levels of education (for depression) and income, peritraumatic dissociation, pre-trauma anxiety, neuroticism, and pre-trauma depression (for depression symptoms). AS was also associated with higher levels of somatic symptoms and mental fatigue with medium effects. Covariates predicting poor somatic and mental fatigue trajectories included identifying as a woman, older age, higher education (for somatic symptoms) and income levels, peritraumatic dissociation, pre-trauma anxiety, neuroticism (for mental fatigue), and pre-trauma somatic symptoms (for somatic symptoms).

3. Discussion

Growth mixture modeling revealed distinct trajectories of APNS, including PTSD, pain, depression, anxiety, sleep disturbance, and somatic symptoms among a large sample of 2,269 trauma survivors presenting to EDs following trauma exposure. Consistent with prior research (deRoos-Cassini et al., 2010), for each APNS construct, trajectories typically indicated at least one class of trauma survivors had more severe and/or persistent symptoms in the eight weeks posttrauma. Findings from the current study support the hypothesis that AS in the aftermath of traumatic event exposure would prospectively predict more severe or persistent trajectories of transdiagnostic APNS including PTSD, depression, anxiety, pain, somatic symptoms, and sleep disturbances in a large sample of individuals with diverse trauma exposures. Indeed, trauma survivors with the most severe and persistent symptoms across APNS reported the highest levels of AS. Results were robust to a variety of important sociodemographic, trauma-related, pre-trauma mental health, and personality-related covariates. These findings are consistent with a large body of previous cross-sectional work linking AS with PTSD symptoms (Lang et al., 2002; Naragon-Gainey, 2010; Taylor, 2003). The current results also build upon limited prospective work of smaller, single trauma-exposed (i.e., sexual assault, campus shooting) samples suggesting AS may prospectively predict PTSD symptoms after trauma (Boffa et al., 2016; Keogh et al., 2002; Short et al., *in press*) by including a large sample of diverse trauma survivors, and examining transdiagnostic APNS.

In terms of mental health-related APNS, elevated AS in the immediate posttrauma period was associated with higher levels and persistence of re-experiencing, avoidance, and hyperarousal symptoms with medium effects ($\eta_p^2 = .03-.11$) in multivariate models adjusting for important sociodemographic, trauma-related, pre-trauma mental health, and personality-related covariates. Further, extending on prior prospective studies of adolescents (Allan et al., 2016) and cross-sectional studies of trauma-exposed adults (Paulus et al., 2018), AS was associated with increased severity and persistence of depression and anxiety with medium to large effects. To our knowledge, one other study has found that AS prospectively predicts anxiety and depression after trauma (specifically sexual assault; Short et al., *in press*), but this is the first study to prospectively link AS with increased anxiety and depression among a large, diverse sample of trauma survivors. Based on the results of the current study and others in the literature, AS may be an important predictor of various mental health-related APNS after trauma exposure.

There were also associations between AS levels in the two weeks posttrauma and physical or somatic APNS. Elevated AS was associated

with worsened pain trajectories (i.e., more severe pain that failed to recover over time) with a small to medium effect. This finding is consistent with prior work linking AS with increased pain severity (Ocañez et al., 2010), including in trauma-exposed samples (Zvolensky et al., 2020); however, to our knowledge this is the first study to suggest that AS is associated with escalating pain after traumatic event exposure. Complementing prior cross-sectional and RCT studies among samples of undergraduates, community individuals with high AS, and psychology clinic outpatients (Levin et al., 2009; Rogers et al., 2016; Short et al., 2015), increased AS had small to medium associations with insomnia symptoms (higher levels that did not recover over time) and nightmares (higher levels that worsened over time) in the aftermath of trauma. Finally, heightened AS was associated with increased somatic symptoms and mental fatigue that worsened over time, with medium effect sizes. This is consistent with a relatively small body of research linking AS with somatic symptoms in the aftermath of trauma (Hensley and Varela, 2008), and trouble concentrating among headache sufferers (Smitherman et al., 2015). Taken together, our findings expand upon prior work linking AS with a variety of physical and somatic symptoms (i.e., pain, sleep disturbance, somatic symptoms, mental fatigue) by suggesting AS is prospectively linked with severity and persistence of these symptoms after trauma exposure.

Regarding strength of associations, all effects were in the small to medium range in multivariate models. Most effects were of medium size, including for re-experiencing, avoidance, hyperarousal, depression, nightmares, anxiety, somatic symptoms, and mental fatigue. Associations between AS and pain and sleep were in the small range. Thus, there was no evidence for specificity or a qualitatively stronger relationship between AS and hyperarousal or anxiety-related constructs. This is in contrast with prior meta-analytic work suggesting AS has stronger associations with hyperarousal symptoms of PTSD compared to re-experiencing or avoidance symptoms (Naragon-Gainey, 2010). These discrepant findings may be due to methodological differences as prior studies often included participants with chronic PTSD, while the current study includes recent trauma survivors who vary in the clinical significance of their PTSD symptoms. It is possible that AS plays a broader predictive role in the immediate aftermath of trauma, reinforcing its importance as a clinical target in preventing APNS after trauma exposure.

The current results also have clinical implications. In the context of a large body of prior work linking AS with trauma-related pathology (Allan et al., 2016; Boffa et al., 2016; Paulus et al., 2018; Short et al., *in press*; Zvolensky et al., 2020), AS may be a transdiagnostic prospective predictor of the development of a variety of APNS among trauma survivors presenting to EDs. Fortunately, AS is a malleable target for treatment, and can be reduced using cognitive behavioral therapy-oriented interventions. These interventions can be delivered via fully computerized treatments as brief as 1 h conducted in a single session (Schmidt et al., 2014). Such AS interventions have been found to reduce symptoms of anxiety, depression, PTSD, and insomnia among individuals with elevated AS (Allan et al., 2015; Schmidt et al., 2014). However, prior work has been conducted among samples of individuals who have established, often chronic, mental health disorders, including experiencing traumas that occurred many years in the past. Future research would benefit from testing whether targeting AS with brief interventions in the immediate aftermath of trauma could mitigate the development of APNS. Considering that AS interventions can be brief and autonomous, they may be feasible for dissemination in the ED setting. If efficacious, this could potentially have a major positive clinical impact in preventing the development of various impairing and distressing APNS ranging from PTSD to depression to pain.

The current findings should be considered in the context of this study's strengths and limitations. Strengths of the current studies include a large sample size of trauma survivors who completed state assessments of their symptoms utilizing validated measures. Regarding limitations, first, future research may benefit from utilizing the full ASI

or ASI-3 (Reiss et al., 1986; Taylor et al., 2007) to assess AS, as the current study used a brief, 3-item measure of AS to accommodate the need to measure many constructs in this large study. In particular, the brief ASI used in the current study only assessed the cognitive and physical components of AS, and did not assess the social component of AS. Therefore, it is unclear how results of the current study apply to the various subfactors of AS. Second, AS was measured in the two weeks posttrauma, rather than prior to trauma exposure. Thus, it remains unclear whether trauma itself may impact the development of AS (for a more detailed discussion, see Short et al., in press). However, regardless of whether AS is impacted by trauma, it may be a malleable risk factor in the immediate aftermath of trauma that could identify those at risk for poor outcomes. Further, even among those with more chronic symptoms, research has indicated that targeting AS is effective in reducing PTSD symptoms (Short et al., 2017). Therefore, although it is important for theoretical reasons to understand whether elevated AS precedes trauma exposure or not, clinically, it remains a useful risk factor to consider using framework developed by Kraemer et al. (1997) as it 1) is correlated with the outcome of interest, 2) occurs prior to the development of the outcome of interest (even if not necessarily prior to trauma exposure itself), and 3) is malleable, with reductions in AS being associated with reductions in PTSD and other APNS. Third, it is important to note that many trauma survivors do not present to emergency care, particularly those who have experienced traumas placing them at high risk for PTSD such as sexual assault (Rennison, 2002). Thus, it is unclear if results would generalize to this population. However, this is a clinically important population with a valuable preventative intervention opportunity in the ED setting.

The current results suggest AS in the two weeks posttrauma is a transdiagnostic predictor of negative outcomes posttrauma, including PTSD, pain, depression, sleep disturbance, anxiety, and somatic symptoms. Future research directions include replicating these findings in diverse samples of trauma survivors, determining mechanisms underlying associations between AS and APNS (particularly considering AS is linked with a diverse array of APNS), and whether targeting AS in the aftermath of trauma would mitigate the development of these symptoms.

Funding

This project was supported by NIMH under U01MH110925, the US Army MRMC, One Mind, and The Mayday Fund. The content is solely responsibility of the authors and does not necessarily represent the official views of any of the funders.

Author Statement

Samuel A. McLean, Ronald C. Kessler, Karestan C. Koenen, Nicole A. Short, Sanne J. H. van Rooij, Vishnu P. Murty, Jennifer S. Stevens, Xinming An, Yinyao Ji, Tanja Jovanovic.

First and Senior authors, working group members (if relevant), writing group members (if relevant), others may be added by core authors, **Conceptualization**, Ideas; formulation or evolution of overarching research goals and aims, EC, First and Senior authors, others can be added.

Stacey L. House, Francesca L. Beaudoin, Xinming An, Jennifer S. Stevens, Donglin Zeng; Thomas C. Neylan; Gari D. Clifford; Tanja Jovanovic; Sarah D. Linnstaedt; Laura T. Germine; Kenneth A. Bollen, Scott L. Rauch, Mark W. Miller, Robert H. Pietrzak, Jutta Joormann, Deanna M. Barch, Diego A. Pizzagalli, John F. Sheridan, Jordan W. Smoller, Steven E. Harte, James M. Elliott, Samuel A. McLean, Ronald C. Kessler, Karestan C. Koenen, writing group members (if relevant), others may be added by core authors, **Methodology**, Development or design of methodology; creation of models, Investigators, Consultants, EC, others can be added.

Nicole A. Short, Xinming An, Yinyao Ji, **Software**, Programming,

software development; designing computer programs; implementation of the computer code and supporting algorithms; testing of existing code components, Team members.

Nicole A. Short, **Validation**, Verification, whether as a part of the activity or separate, of the overall replication/reproducibility of results/experiments and other research outputs, Team members.

Nicole A. Short, Xinming An, Yinyao Ji, **Formal analysis**, Application of statistical, mathematical, computational, or other formal techniques to analyze or synthesize study data, Team members.

Stacey L. House, Francesca L. Beaudoin, Xinming An, Jennifer S. Stevens, Donglin Zeng, Thomas C. Neylan, Gari D. Clifford, Tanja Jovanovic, Sarah D. Linnstaedt, Laura T. Germine, Kenneth A. Bollen, Scott L. Rauch, John P. Haran, Christopher Lewandowski, Paul I. Musey Jr., Phyllis L. Hendry, Sophia Sheikh, Christopher W. Jones, Brittany E. Panches, Robert A. Swor, Vishnu P. Murty, Meghan E. McGrath, Lauren A. Hudak, Jose L. Pascual, Mark J. Seamon, Elizabeth M. Datner, Claire Pearson, David A. Peak, Roland C. Merchant, Robert M. Domeier, Niels K. Rathlev, Brian J. O'Neil, Paulina Sergot, Leon D. Sanchez, Steven E. Bruce, Samuel A. McLean, Ronald C. Kessler, Karestan C. Koenen, **Investigation**, Conducting a research and investigation process, specifically performing the experiments, or data/evidence collection, Investigators, Site PIs, EC, others can be added.

Stacey L. House, Francesca L. Beaudoin, Xinming An, Jennifer S. Stevens; Donglin Zeng; Thomas C. Neylan; Gari D. Clifford; Tanja Jovanovic; Sarah D. Linnstaedt; Laura T. Germine; Kenneth A. Bollen; Scott L. Rauch, John P. Haran, Christopher Lewandowski, Paul I. Musey Jr., Phyllis L. Hendry, Sophia Sheikh, Christopher W. Jones, Brittany E. Panches, Robert A. Swor, Vishnu P. Murty, Meghan E. McGrath, Lauren A. Hudak, Jose L. Pascual, Mark J. Seamon, Elizabeth M. Datner, Claire Pearson, David A. Peak, Roland C. Merchant, Robert M. Domeier, Niels K. Rathlev, Brian J. O'Neil, Paulina Sergot, Leon D. Sanchez, Steven E. Bruce, Samuel A. McLean, Ronald C. Kessler, Karestan C. Koenen, **Resources**, Provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or other analysis tools, Investigators, Site PIs, EC, others can be added.

Stacey L. House, Francesca L. Beaudoin, Xinming An, Jennifer S. Stevens; Donglin Zeng; Thomas C. Neylan; Gari D. Clifford; Tanja Jovanovic; Sarah D. Linnstaedt; Laura T. Germine; Kenneth A. Bollen, Scott L. Rauch, Samuel A. McLean, Ronald C. Kessler; Karestan C. Koenen, Xinming An, Yinyao Ji, **Data Curation**, Management activities to annotate (produce metadata), scrub data and maintain research data (including software code, where it is necessary for interpreting the data itself) for initial use and later reuse, Investigators, EC, others can be added. Nicole A. Short., **Writing - Original Draft**, Preparation, creation and/or presentation of the published work, specifically writing the initial draft (including substantive translation), Team members.

Nicole A. Short, Sanne J. H. van Rooij, Vishnu P. Murty, Jennifer S. Stevens, Xinming An, Yinyao Ji, Samuel A. McLean, Stacey L. House, Francesca L. Beaudoin, Donglin Zeng, Thomas C. Neylan, Gari D. Clifford, Sarah D. Linnstaedt, Laura T. Germine, Kenneth A. Bollen, Scott L. Rauch, John P. Haran, Christopher Lewandowski, Paul I. Musey Jr., Phyllis L. Hendry, Sophia Sheikh, Christopher W. Jones, Britany E. Panches, Robert A. Swor, Meghan E. McGrath Laurant A. Hudak, Jose L. Pascual, Mark J. Seamon, Elizabeth M. Datner, Claire Pearson, David A. Peak, Roland C. Merchant, Robert M. Domeier, Niels K. Rathlev, Brian J. O'Neil, Paulina Sergot, Leon D. Sanchez, Steven E. Bruce, Robert H. Pietrzak, Jutta Joormann, Deanna M. Barch, Diego A. Pizzagalli, John F. Sheridan, Jordan W. Smoller, Steven E. Harte, James M. Elliott, Ronald C. Kessler, Karestan C. Koenen, Tanja Jovanovic:

All authors who responded confirming authorship/edits, **Writing - Review & Editing**, Preparation, creation and/or presentation of the published work by those from the original research group, specifically critical review, commentary or revision – including pre-or post-publication stages, Responding authors.

Nicole A. Short, Xinming An, Yinyao Ji, **Visualization**, Preparation, creation and/or presentation of the published work, specifically

visualization/data presentation, Team members Samuel A. McLean, Ronald C. Kessler, Karestan C. Koenen, Nicole A. Short, Tanja Jovanovic, **Supervision**, Oversight and leadership responsibility for the research activity planning and execution, including mentorship external to the core team, EC, First and Senior authors, others can be added.

Stacey L. House, Francesca L. Beaudoin, John P. Haran, Christopher Lewandowski, Paul I. Musey Jr., Phyllis L. Hendry, Sophia Sheikh, Christopher W. Jones, Brittany E. Panches, Robert A. Swor, Vishnu P. Murty, Meghan E. McGrath, Lauren A. Hudak, Jose L. Pascual, Mark J. Seamon, Elizabeth M. Datner, Claire Pearson, David A. Peak, Roland C. Merchant, Robert M. Domeier, Niels K. Rathlev, Brian J. O'Neil, Paulina Sergot, Leon D. Sanchez, Steven E. Bruce, Samuel A. McLean, Ronald C. Kessler, Karestan C. Koenen, **Project administration**, Management and coordination responsibility for the research activity planning and execution, Site PIs (including SLH and FLB), EC, others can be added.

Samuel A. McLean, Ronald C. Kessler, Karestan C. Koenen, **Funding acquisition**, Acquisition of the financial support for the project leading to this publication, EC, others can be added.

Declaration of competing interest

Dr. Neylan has received research support from NIH, VA, and Rainwater Charitable Foundation, and consulting income from Jazz Pharmaceuticals. In the last three years Dr. Clifford has received research funding from the NSF, NIH and LifeBell AI, and unrestricted donations from AliveCor, Amazon Research, the Center for Discovery, the Gordon and Betty Moore Foundation, MathWorks, Microsoft Research, the Gates Foundation, Google, One Mind Foundation, and Samsung Research. Dr. Clifford has financial interest in AliveCor, and receives unrestricted funding from the company. He also is the CTO of MindChild Medical and CSO of LifeBell AI and has ownership in both companies. These relationships are unconnected to the current work. Dr. Rauch reports grants from NIH during the conduct of the study; personal fees from SOBP (Society of Biological Psychiatry) paid role as secretary, other from Oxford University Press royalties, other from APP (American Psychiatric Publishing Inc.) royalties, other from VA (Veterans Administration) per diem for oversight committee, and other from Community Psychiatry/Mindpath Health paid board service, including equity outside the submitted work; other from National Association of Behavioral Healthcare for paid Board service; and Leadership roles on Board or Council for SOBP, ADA (Anxiety and Depression Association of America), and NNDC (National Network of Depression Centers). Dr. Sophia Sheikh has received funding from the Florida Medical Malpractice Joint Underwriter's Association Dr. Alvin E. Smith Safety of Healthcare Services Grant; Allergan Foundation; the NIH/NIA-funded Jacksonville Aging Studies Center (JAX-ASCENT; R33AG05654); and the Substance Abuse and Mental Health Services Administration (1H79TI083101-01); and the Florida Blue Foundation. Dr. Jones has no competing interests related to this work, though he has been an investigator on studies funded by AstraZeneca, Janssen, Holigic, Inc, and Ophirex. Dr. Datner serves as Medical Advisor for Cayaba Care. Dr. Joormann receives consulting payments from Janssen Pharmaceuticals. Dr. Barch has received function from the NIMH, NIDA, and the American Foundation for Suicide Prevention, and consults for Boehringer-Ingelheim. Over the past 3 years, Dr. Pizzagalli has received consulting fees from Albright Stonebridge Group, Boehringer Ingelheim, Compass Pathways, Concert Pharmaceuticals, Engrail Therapeutics, Neumora Therapeutics (former BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; honoraria from the Psychonomic Society (for editorial work) and Alkermes, and research funding from NIMH, Dana Foundation, Brain and Behavior Research Foundation, and Millennium Pharmaceuticals. In addition, he has received stock options from Neumora Therapeutics (former BlackThorn Therapeutics), Compass Pathways, Engrail Therapeutics, and Neuroscience Software. Dr. Harte has no competing interests related to this work, though in the last three

years he has received research funding from Aptinyx and Arbor Medical Innovations, and consulting payments from Aptinyx, Heron Therapeutics, and Eli Lilly. Dr. Elliott reports support from the National Institutes of Health (NIH) through Grant Numbers R01HD079076 & R03HD094577: Eunice Kennedy Shriver National Institute of Child Health & Human Development; National Center for Medical Rehabilitation Research. He also reports funding from New South Wales Health, Spinal Cord Injury Award (2020–2025) and consulting fees (<\$15,000 per annum) from Orofacial Therapeutics, LLC. In the past 3 years, Dr. Kessler was a consultant for Datastat, Inc., Holmusk, RallyPoint Networks, Inc., and Sage Pharmaceuticals. He has stock options in Mirah, PYM, and Roga Sciences.

PTSD = posttraumatic stress disorder. Clinical outcomes were calculated using the following cut-offs: Clinically significant new or worsening pain = increased pain from pre-to posttrauma by ≥ 2 points on the pain numeric rating scale (Bijur et al., 2003); PTSD ≥ 31 on the Posttraumatic Stress Disorder Checklist (PCL; Weathers et al., 2013); Depression ≥ 60 on the Patient-Reported Outcome Measurement Information System (PROMIS; Cella et al., 2010); Insomnia = Insomnia Severity Index scores of at least 15 (Morin et al., 2011). Of note, a brief PROMIS anxiety scale was administered, precluding the ability to assess clinically significant symptoms based on typical cut-off scores. Thus, means for anxiety are reported (range = 0–16).

Acknowledgments

The investigators wish to thank the trauma survivors participating in the AURORA Study. Their time and effort during a challenging period of their lives make our efforts to improve recovery for future trauma survivors possible. Data and/or research tools used in the preparation of this manuscript were obtained from the National Institute of Mental Health (NIMH) Data Archive (NDA). NDA is a collaborative informatics system created by the National Institutes of Health to provide a national resource to support and accelerate research in mental health. Dataset identifier: NIMH Data Archive Digital Object Identifier 10.15154/1526377. This manuscript reflects the views of the authors and may not reflect the opinions or views of the NIH or of the Submitters submitting original data to NDA. Mindstrong Health provided some of the hardware and software used to perform study assessments. Support for title page creation and format was provided by AuthorArranger, a tool developed at the National Cancer Institute.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jpsychires.2022.09.027>.

References

- Allan, N.P., Felton, J.W., Lejuez, C.W., MacPherson, L., Schmidt, N.B., 2016. Longitudinal investigation of anxiety sensitivity growth trajectories and relations with anxiety and depression symptoms in adolescence. *Dev. Psychopathol.* 28 (2), 459–469.
- Allan, N.P., Short, N.A., Albanese, B.J., Keough, M.E., Schmidt, N.B., 2015. Direct and mediating effects of an anxiety sensitivity intervention on posttraumatic stress disorder symptoms in trauma-exposed individuals. *Cognit. Behav. Ther.* 44 (6), 512–524.
- American Psychiatric Association, 2013. *Diagnostic and Statistical Manual of Mental Disorders*, fifth ed. American Psychiatric Publishing, Arlington, VA.
- Asmundson, G.J., Coons, M.J., Taylor, S., Katz, J., 2002. PTSD and the experience of pain: research and clinical implications of shared vulnerability and mutual maintenance models. *Can. J. Psychiatr.* 47 (10), 930–937.
- Beaudoin, F.L., An, X., Basu, A., Ji, Y., Liu, M., Kessler, R.C., Dougherty, R.F., McLean, S. A., Under Review. Use of Serial Smartphone-Based Assessments to Characterize Diverse Neuropsychiatric Symptom Trajectories in a Large Trauma Survivor Cohort.
- Bijur, P.E., Latimer, C.T., Gallagher, E.J., 2003. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. *Acad. Emerg. Med.* 10 (4), 390–392.
- Boffa, J.W., Norr, A.M., Raines, A.M., Albanese, B.J., Short, N.A., Schmidt, N.B., 2016. Anxiety sensitivity prospectively predicts posttraumatic stress symptoms following a campus shooting. *Behav. Ther.* 47 (3), 367–376.

- Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., Amtmann, D., Bode, R., Buysse, D., Choi, S., 2010. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *J. Clin. Epidemiol.* 63 (11), 1179–1194.
- Cohen, J., 1988. Statistical power analysis for the behavioral sciences. *Rehabil. Psychol.* In: Erlbaum Associates, L., Hillsdale, N.J., deRoon-Cassini, T.A., Mancini, A.D., Rusch, M.D., Bonanno, G.A. (Eds.), 2010. *Psychopathology and Resilience Following Traumatic Injury: a Latent Growth Mixture Model Analysis*, second ed., 55, p. 1.
- Farrar, J.T., Young Jr., J.P., LaMoreaux, L., Werth, J.L., Poole, R.M., 2001. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain* 94 (2), 149–158.
- Gosling, S.D., Rentfrow, P.J., Swann Jr., W.B., 2003. A very brief measure of the Big-Five personality domains. *J. Res. Pers.* 37 (6), 504–528.
- Grenga, P.N., Paulzak, A.N., Bodkin, R.P., 2017. Management of the MVC patient: pearls and pitfalls. <http://www.emdocs.net/ed-management-of-the-mva-patient-pearls-and-pitfalls/>. (Accessed 27 June 2022). Accessed.
- Hensley, L., Varela, R.E., 2008. PTSD symptoms and somatic complaints following Hurricane Katrina: the roles of trait anxiety and anxiety sensitivity. *J. Clin. Child Adolesc. Psychol.* 37 (3), 542–552.
- IBM Corp, 2019. IBM SPSS Statistics for Windows, Version 26.0. IBM Corp, Armonk, NY.
- Kenardy, J., Edmed, S.L., Shourie, S., Warren, J., Crothers, A., Brown, E.A., Cameron, C. M., Heron-Delaney, M., 2018. Changing patterns in the prevalence of posttraumatic stress disorder, major depressive episode and generalized anxiety disorder over 24 months following a road traffic crash: results from the UQ SUPPORT study. *J. Affect. Disord.* 236, 172–179.
- Keogh, E., Ayers, S., Francis, H., 2002. Does anxiety sensitivity predict post-traumatic stress symptoms following childbirth? A preliminary report. *Cognit. Behav. Ther.* 31 (4), 145–155.
- Kessler, R.C., 2000. Posttraumatic stress disorder: the burden to the individual and to society. *J. Clin. Psychiatr.* 61 (S5), 4–12.
- Kessler, R.C., Ressler, K.J., House, S.L., Beaudoin, F.L., An, X., Stevens, J.S., Zeng, D., Neylan, T.C., Linnstaedt, S.D., Germaine, L.T., 2020. Socio-demographic and trauma-related predictors of PTSD within 8 weeks of a motor vehicle collision in the AURORA study. *Mol. Psychiatr.* 1–14.
- Kilpatrick, D.G., Resnick, H.S., Milanak, M.E., Miller, M.W., Keyes, K.M., Friedman, M.J., 2013. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. *J. Trauma Stress* 26 (5), 537–547.
- Kraemer, H.C., Kazdin, A.E., Offord, D.R., Kessler, R.C., Jensen, P.S., Kupfer, D.J., 1997. Coming to terms with the terms of risk. *Arch. Gen. Psychiatr.* 54 (4), 337–343.
- Lang, A.J., Kennedy, C.M., Stein, M.B., 2002. Anxiety sensitivity and PTSD among female victims of intimate partner violence. *Depress. Anxiety* 16 (2), 77–83.
- Levin, R., Lantz, E., Fireman, G., Spendlove, S., 2009. The relationship between disturbed dreaming and somatic distress: a prospective investigation. *J. Nerv. Ment. Dis.* 197 (8), 606–612.
- Loftis, K.L., Price, J., Gillich, P.J., 2018. Evolution of the abbreviated injury scale: 1990–2015. *Traffic Inj. Prev. M.T.* 19 (Suppl. 2), S109–S113.
- McHugh, R.K., Gratz, K.L., Tull, M.T., 2017. The role of anxiety sensitivity in reactivity to trauma cues in treatment-seeking adults with substance use disorders. *Compr. Psychiatr.* 78, 107–114.
- McLean, S.A., Kirsch, N.L., Tan-Schriner, C.U., Sen, A., Frederiksen, S., Harris, R.E., Maixner, W., Maio, R.F., 2009. Health status, not head injury, predicts concussion symptoms after minor injury. *Am. J. Emerg. Med.* 27 (2), 182–190.
- McLean, S.A., Ressler, K., Koenen, K.C., Neylan, T., Germaine, L., Jovanovic, T., Clifford, G.D., Zeng, D., An, X., Linnstaedt, S., 2019. The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure. *Mol. Psychiatr.* 1–14.
- McNally, R.J., 2002. Anxiety sensitivity and panic disorder. *Biol. Psychiatr.* 52 (10), 938–946.
- Michaels, A.J., Michaels, C.E., Moon, C.H., Smith, J.S., Zimmerman, M.A., Taheri, P.A., Peterson, C., 1999. Posttraumatic stress disorder after injury: impact on general health outcome and early risk assessment. *J. Trauma and Acute Care Surg.* 47 (3), 460–467.
- Milanak, M.E., Zuromski, K.L., Cero, I., Wilkerson, A.K., Resnick, H.S., Kilpatrick, D.G., 2019. Traumatic event exposure, posttraumatic stress disorder, and sleep disturbances in a national sample of US adults. *J. Trauma Stress* 32 (1), 14–22.
- Momartin, S., Silove, D., Manicavasagar, V., Steel, Z., 2004. Comorbidity of PTSD and depression: associations with trauma exposure, symptom severity and functional impairment in Bosnian refugees resettled in Australia. *J. Affect. Disord.* 80 (2–3), 231–238.
- Morin, C.M., Belleville, G., Bélanger, L., Ivers, H., 2011. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. *Sleep* 34 (5), 601–608.
- Muthén, L.K., Muthén, B.O., 1998–2017. In: Muthén, M. (Ed.), *Mplus User's Guide*. Los Angeles, CA.
- Naragon-Gainey, K., 2010. Meta-analysis of the relations of anxiety sensitivity to the depressive and anxiety disorders. *Psychol. Bull.* 136 (1), 128.
- National Center for PTSD, 2019. PTSD Checklist for DSM-5 (PCL-5). <https://www.ptsd.va.gov/professional/assessment/adult-sr/ptsd-checklist.asp>. 2019.
- Ocañez, K.L., Kathryn McHugh, R., Otto, M.W., 2010. A meta-analytic review of the association between anxiety sensitivity and pain. *Depress. Anxiety* 27 (8), 760–767.
- Paulus, D.J., Gallagher, M.W., Bartlett, B.A., Tran, J., Vujanovic, A.A., 2018. The unique and interactive effects of anxiety sensitivity and emotion dysregulation in relation to posttraumatic stress, depressive, and anxiety symptoms among trauma-exposed firefighters. *Compr. Psychiatr.* 84, 54–61.
- Pennebaker, J., Watson, D., 1991. *The Psychology of Somatic Symptoms, Current Concepts of Somatization*, LJ Kirmayer, JM Robbins. American Psychiatric Press Inc, Washington DC.
- Potter, S., Leigh, E., Wade, D., Fleminger, S., 2006. The Rivermead post concussion symptoms questionnaire. *J. Neurol.* 253 (12), 1603–1614.
- R Core Team, 2022. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria.
- Reiss, S., Peterson, R.A., Gursky, D.M., McNally, R.J., 1986. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. *Behav. Res. Ther.* 24 (1), 1–8.
- Rennison, C.A., 2002. Rape and sexual assault: reporting to police and medical attention, 1992–2000. In: Justice, U.D.o. (Ed.), *Office of Justice Programs. Bureau of Justice Statistics*.
- Richardson, J.T.E., 2011. Eta squared and partial eta squared as measurements of effect size in educational research. *Educ. Res. Rev.* 6, 135–147.
- Roberts, A.L., Gilman, S.E., Breslau, J., Breslau, N., Koenen, K.C., 2011. Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. *Psychol. Med.* 41 (1), 71.
- Rogers, M.L., Tucker, R.P., Law, K.C., Michaels, M.S., Anestis, M.D., Joiner, T.E., 2016. Manifestations of overarousal account for the association between cognitive anxiety sensitivity and suicidal ideation. *J. Affect. Disord.* 192, 116–124.
- Santiago, P.N., Ursano, R.J., Gray, C.L., Pynoos, R.S., Spiegel, D., Lewis-Fernandez, R., Friedman, M.J., Fullerton, C.S., 2013. A systematic review of PTSD prevalence and trajectories in DSM-5 defined trauma exposed populations: intentional and non-intentional traumatic events. *PLoS One* 8 (4), e59236.
- Schmidt, N.B., Capron, D.W., Raines, A.M., Allan, N.P., 2014. Randomized clinical trial evaluating the efficacy of a brief intervention targeting anxiety sensitivity cognitive concerns. *J. Consult. Clin. Psychol.* 82 (6), 1023.
- Short, N.A., Allan, N.P., Raines, A.M., Schmidt, N.B., 2015. The effects of an anxiety sensitivity intervention on insomnia symptoms. *Sleep Med.* 16 (1), 152–159.
- Short, N.A., Allan, N.P., Schmidt, N.B., 2018. Sleep disturbance as a predictor of affective functioning and symptom severity among individuals with PTSD: an ecological momentary assessment study. *Behav. Res. Ther.* 97, 146–153.
- Short, N.A., Boffa, J.W., Norr, A.M., Albanese, B.J., Allan, N.P., Schmidt, N.B., 2017. Randomized clinical trial investigating the effects of an anxiety sensitivity intervention on posttraumatic stress symptoms: a replication and extension. *J. Trauma Stress*.
- Short, N.A., Lechner, M., Bell, K., Black, J., Buchanan, J., Ho, J., Reed, G., Corzine, A., Rivello, R., Martin, S.L., Liberzon, I., Rauch, S.A.M., McLean, S.A., 2022. Anxiety sensitivity prospectively predicts increased acute posttraumatic stress and related symptoms after sexual assault. *J. Trauma Stress* in press.
- Smitherman, T.A., Davis, R.E., Walters, A.B., Young, J., Houle, T.T., 2015. Anxiety sensitivity and headache: diagnostic differences, impact, and relations with perceived headache triggers. *Cephalalgia* 35 (8), 710–721.
- Smits, J.A., Otto, M.W., Powers, M.B., Baird, S.O., 2019. Anxiety Sensitivity as a Transdiagnostic Treatment Target, the Clinician's Guide to Anxiety Sensitivity Treatment and Assessment. Elsevier, pp. 1–8.
- Taylor, S., 2003. Anxiety sensitivity and its implications for understanding and treating PTSD. *J. Cognit. Psychother.* 17 (2), 179–186.
- Taylor, S., Zvolensky, M.J., Cox, B.J., Deacon, B., Heimberg, R.G., Ledley, D.R., Abramowitz, J.S., Holaway, R.M., Sandin, B., Stewart, S.H., 2007. Robust dimensions of anxiety sensitivity: development and initial validation of the Anxiety Sensitivity Index-3. *Psychol. Assess.* 19 (2), 176.
- Ulirsch, J., Ballina, L., Soward, A., Rossi, C., Hauda, W., Holbrook, D., Wheeler, R., Foley, K.A., Batts, J., Collette, R., 2014. Pain and somatic symptoms are sequelae of sexual assault: results of a prospective longitudinal study. *Eur. J. Pain* 18 (4), 559–566.
- Weathers, F.W., Litz, B.T., Keane, T.M., Palmieri, P.A., Marx, B.P., Schnurr, P.P., 2013. The PTSD Checklist for DSM-5 (PCL-5). National Center for PTSD.
- Ziobrowski, H.N., Kennedy, C.J., Ustun, B., House, S.L., Beaudoin, F.L., An, X., Zeng, D., Bollen, K.A., Petukhova, M., Sampson, N.A., 2021. Development and validation of a model to predict posttraumatic stress disorder and major depression after a motor vehicle collision. *JAMA Psychiatr.* 78 (11), 1228–1237.
- Zvolensky, M.J., Rogers, A.H., Shepherd, J.M., Vujanovic, A.A., Bakshshaie, J., 2020. Anxiety sensitivity and opioid misuse and dependence among trauma-exposed adults with chronic pain. *J. Behav. Med.* 43 (2), 174–184.